Controlling the Phenotype of Tumor-Infiltrating Macrophages via the PHD-HIF Axis Inhibits Tumor Growth in a Mouse Model
Shunji Nishide,
Shinji Matsunaga,
Masayuki Shiota,
Takehiro Yamaguchi,
Shojiro Kitajima,
Yoichi Maekawa,
Norihiko Takeda,
Michio Tomura,
Junji Uchida,
Katsuyuki Miura,
Tatsuya Nakatani,
Shuhei Tomita
Affiliations
Shunji Nishide
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Shinji Matsunaga
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Masayuki Shiota
Division of Research Support Platform, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Takehiro Yamaguchi
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Shojiro Kitajima
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Yoichi Maekawa
Department of Parasitology and Infectious Diseases, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Domain of Integrated Life Systems, Center for Highly Advanced Integration of Nano and Life Sciences, Gifu University, Gifu 501-1193, Japan
Norihiko Takeda
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Michio Tomura
Laboratory of Immunology, Faculty of Pharmacy, Osaka Ohtani University, Osaka 584-8540, Japan
Junji Uchida
Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Katsuyuki Miura
Department of Applied Pharmacology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Tatsuya Nakatani
Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Shuhei Tomita
Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan; Corresponding author
Summary: The tumor microenvironment (TME) polarizes tumor-infiltrating macrophages toward tumor support. Macrophage-abundant tumors are highly malignant and are the cause of poor prognosis and therapeutic resistance. In this study, we show that the prolyl hydroxylase (PHD) inhibitor FG-4592 (FG) inhibits tumor growth of macrophage-abundant tumors and prolongs mouse survival. FG not only normalizes tumor vessels and improves tumor oxygenation but also directly affects macrophages and activates phagocytosis through the PHD-hypoxia-inducible factor (HIF) axis. Remarkably, FG can promote phagocytic ability of the Ly6Clo subset of tumor-infiltrating macrophages, leading to tumor growth inhibition. Moreover, Ly6Cneg macrophages contributed to blood vessel normalization. Using a malignant tumor mouse model, we characterized macrophage function and subsets. Altogether, our findings suggest that the PHD inhibitor can promote the anti-tumor potential of macrophages to improve cancer therapy. : Microenvironment; Immune Response; Cancer Subject Areas: Microenvironment, Immune Response, Cancer